Atossa Genetics Inc. (ATOS) had a wild week last week after announcing that its proprietary oral Endoxifen was granted "Expanded Access" by the FDA for Post-Mastectomy Treatment for a U.S. Breast Cancer Patient. Third time was apparently a charm since the company announced it was originally given Expanded Access prior to the operation on December 3 and positive results were reported on February 7. Both updates resulted in a lot of volume being traded on the stock on those particular days but minimal price movement and no follow up. The announcement of continued